Group items tagged

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics. On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model. Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face. "To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.

A new report from the Association of the British Pharmaceutical Industry (ABPI) has highlighted that while the NHS has made significant progress in the introduction of cell and gene therapies, the health service must "do more to get ready for the arrival of the advanced therapies of the future." The ABPI noted that advanced therapies, also known as Advanced Therapy Medicinal Products (ATMPs), offer hope for diseases previously deemed "untreatable." ATMPs have already been introduced for treating some rarer conditions, including haemophilia, spinal muscular atrophy, and a rare disease that causes blindness. "In some cases, these therapies can transform people's lives with just a single treatment," the Association said. The ABPI's report, titled Unlocking Access to Future ATMPs in the UK: Comparing International Approaches, emphasises the need for the NHS to revise its payment strategies for upcoming therapies.

Ochsner is led by the President and CEO, Warner Thomas - a leader with a strategic vision. He exemplifies courage in a time of change to ensure that the organization positively embraces disruption and continues to move in the right direction that is best for its patients.